Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
They need to know how you are feeling so they can adjust your dosing schedule if necessary
Always consult a licensed provider before starting or modifying any treatment
Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4): a randomised, double-blind, placebo-controlled, phase 3 trial
Weight loss results vary significantly by specific medication and dose: Semaglutide 2.4 mg (Wegovy): Clinical trials (STEP program) showed average weight reductions of 1517% at 68 weeks Tirzepatide (Zepbound): SURMOUNT trials demonstrated weight reductions of 1522% at 72 weeks, with results varying between populations with and without diabetes Liraglutide 3 mg (Saxenda): Typically produces 510% weight loss over 56 weeks The rate of weight loss is not linear
